Alex DTx Platform

The smarter way to launch Digital Therapeutics.

We provide the platform that enables our partners to effectively and reliably launch new digital therapeutics (DTx) by leveraging existing insights, modules, processes and data.

Discover our Platform
Our Digital Therapeutics

Evidence-based digital interventions that deliver novel and personalized care

Digital Therapeutics (DTx) are evidence-based therapeutic interventions delivered as mobile software applications. They undergo rigorous clinical and regulatory review, ensuring the same high standards of efficacy and safety as with traditional drugs. A DTx can be prescribed by a physician alongside a drug or therapy or as a stand-alone treatment.

Learn more about DTx

A complete smoking cessation program treating nicotine addiction

Eila® is a 12-week program for the treatment of tobacco dependence. The DTx is currently undergoing clinical trial in Germany to provide an evidence-based, clinically validated, and personalized digital therapy to patients.

In collaboration with:


Prescription DTx to increase quality of life for PF patients.

The comprehensive DTx will provide treatment for currently undertreated symptoms associated with PF, such as low mood and anxiety, improving the patient's quality of life.

In collaboration with:

Alex – Quit Smoking

The all-inclusive digital quit smoking coach.

Currently available for download in over 150 countries globally through the Apple App Store and Google Play.

Go to

Use the Alex DTx Platform to launch novel digital treatments

We partner with pharma, insurance and healthcare companies in developing and launching novel DTx treatments.

Get in touch

Empowering patients globally

With a patient-centric mentality, we are driven by our goal of delivering targeted personalized care. Our novel DTx treatments are developed in collaboration with patient groups and deliver targeted, personalized care to patients with overlooked symptoms.

More about us
Friends & Partners